Increased coexpression of c-KIT and FLT3 receptors on myeloblasts: Independent predictor of poor outcome in pediatric acute myeloid leukemia

Cytometry Part B - Clinical Cytometry

Volumn 84, Issue 6, 2013, Pages 390-397

  Sharawat, Surender Kumar ^a,c   Gupta, Ritu ^a,b,c   Raina, Vinod ^a,c   Kumar, Lalit ^a,c   Sharma, Atul ^a,c   Iqbal, Sobuhi ^a,c   Bakhshi, Radhika ^b   Vishnubhatla, Sreenivas ^b,c   Bakhshi, Sameer ^a,c  

^a INSTITUTE ROTARY CANCER HOSPITAL   (India)

^b UNIVERSITY OF DELHI   (India)

^c ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Acute Myeloid Leukemia; CD117; CD135; Coexpression; Flow cytometry

Indexed keywords

CD135 ANTIGEN; CYTARABINE; DAUNORUBICIN; HEMOGLOBIN; STEM CELL FACTOR RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ANTIGEN EXPRESSION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; CYTOGENETICS; DRUG MEGADOSE; EVENT FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN CELL; INFANT; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MYELOBLAST; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; SCHOOL CHILD;

ACUTE MYELOID LEUKEMIA; CD117; CD135; COEXPRESSION; FLOW-CYTOMETRY;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; FEMALE; FLOW CYTOMETRY; FMS-LIKE TYROSINE KINASE 3; GENE EXPRESSION REGULATION, LEUKEMIC; GRANULOCYTE PRECURSOR CELLS; HUMANS; INFANT; LEUKEMIA, MYELOID, ACUTE; LEUKOCYTE COUNT; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-KIT;

EID: 84887448340     PISSN: 15524949     EISSN: 15524957     Source Type: Journal    
DOI: 10.1002/cyto.b.21098     Document Type: Article

References (15)

1. Bene MC, Bernier M, Casasnovas RO, Castoldi G, Knapp W, Lanza F, Ludwig WD, Matutes E, Orfao A, Sperling C, et al. The reliability and specificity of c-KIT for the diagnosis of acute myeloid leukemias and undifferentiated leukemias. The European Group for the Immunological Classification of Leukemias (EGIL). Blood 1998; 92: 596-599.
2. Ashman LK, Roberts MM, Gadd SJ, Cooper SJ, Juttner CA,. Expression of a 150-kD cell surface antigen identified by monoclonal antibody YB5. B8 is associated with poor prognosis in acute non-lymphoblastic leukaemia. Leuk Res 1988; 12: 923-928.
3. Reuss-Borst MA, Bühring HJ, Schmidt H, Müller CA. AML,: Immunophenotypic heterogeneity and prognostic significance of c-KIT expression. Leukemia 1994; 8: 258-263.
4. Graf M, Hecht K, Reif S, Pelka-Fleischer R, Pfister K, Schmetzer H,. Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): Implications for future therapeutical strategies. Eur J Haematol 2004; 72: 89-106.
5. Liu Yin JA, Wheatley K, Rees JK, Burnett AK,. Comparison of 'sequential' versus 'standard' chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): Results of the UK Medical Research Council AML-R trial. Br J Haematol 2001; 113: 713-726.
6. Stacchini A, Fubini L, Severino A, Sanavio F, Aglietta M, Piacibello W,. Expression of type III receptor tyrosine kinases FLT3 and KIT and responses to their ligands by acute myeloid leukemia blasts. Leukemia 1996; 10: 1584-1591.
7. McKenna HJ, Smith FO, Brasel K, Hirschstein D, Bernstein ID, Williams DE, Lyman SD,. Effects of flt3 ligand on acute myeloid and lymphocytic leukemic blast cells from children. Exp Hematol 1996; 24: 378-385.
8. Ikeda H, Kanakura Y, Tamaki T, Kuriu A, Kitayama H, Ishikawa J, Kanayama Y, Yonezawa T, Tarui S, Griffin JD,. Expression and functional role of the proto-oncogene c-KIT in acute myeloblastic leukemia cells. Blood 1991; 78: 2962-2968.
9. Wells SJ, Bray RA, Stempora LL, Farhi DC., CD117/CD34 expression in leukemic blasts. Am J Clin Pathol 1996; 106: 192-195.
10. Bradstock K, Matthews J, Benson E, Page F, Bishop J,. Prognostic value of immunophenotyping in acute myeloid leukemia. Australian Leukaemia Study Group. Blood 1994; 84: 1220-1225.
11. Morita S, Tsuchiya S, Fujie H, Itano M, Ohashi Y, Minegishi M, Imaizumi M, Endo M, Takano N, Konno T,. Cell surface c-KIT receptors in human leukemia cell lines and pediatric leukemia: Selective preservation of c-KIT expression on megakaryoblastic cell lines during adaptation to in vitro culture. Leukemia 1996; 10: 102-105.
12. Ozeki K, Kiyoi H, Hirose Y, Iwai M, Ninomiya M, Kodera Y, Miyawaki S, Kuriyama K, Shimazaki C, Akiyama H, et al. Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia. Blood 2004; 103: 1901-1908.
13. Müller-Tidow C, Schwäble J, Steffen B, Tidow N, Brandt B, Becker K, Schulze-Bahr E, Halfter H, Vogt U, Metzger R, et al. High-throughput analysis of genome-wide receptor tyrosine kinase expression in human cancers identifies potential novel drug targets. Clin Cancer Res 2004; 10: 1241-1249.
14. Stone RM, DeAngelo DJ, Klimek V, Galinsky I, Estey E, Nimer SD, Grandin W, Lebwohl D, Wang Y, Cohen P, et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 2005; 105: 54-60.
15. Spiekermann K, Dirschinger RJ, Schwab R, Bagrintseva K, Faber F, Buske C, Schnittger S, Kelly LM, Gilliland DG, Hiddemann W,. The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3. Blood 2003; 101: 1494-1504.